CN114599379A - 一种用于预防或治疗脓毒症的药物组合物、试剂盒及其应用和治疗方法 - Google Patents

一种用于预防或治疗脓毒症的药物组合物、试剂盒及其应用和治疗方法 Download PDF

Info

Publication number
CN114599379A
CN114599379A CN202080002489.XA CN202080002489A CN114599379A CN 114599379 A CN114599379 A CN 114599379A CN 202080002489 A CN202080002489 A CN 202080002489A CN 114599379 A CN114599379 A CN 114599379A
Authority
CN
China
Prior art keywords
mitochondria
sepsis
pharmaceutical composition
mice
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080002489.XA
Other languages
English (en)
Inventor
唐凌峰
吴忆华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Maitang Biotechnology Co ltd
Original Assignee
Shenzhen Maitang Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Maitang Biotechnology Co ltd filed Critical Shenzhen Maitang Biotechnology Co ltd
Publication of CN114599379A publication Critical patent/CN114599379A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

为克服现有脓毒症的治疗方法和治疗药物存在治疗效果不佳和副作用较大的问题，本发明提供了一种用于预防或治疗脓毒症的药物组合物，包括具有生理活性的线粒体作为活性成分。同时，本发明还公开了包括上述药物组合物的试剂盒。本发明的另一方面公开了线粒体在制备用于预防或治疗脓毒症的药物、药物组合物或试剂盒中的应用。本发明设置不同给药方式(如腹腔注射IP、静脉注射IV、皮下注射SC)、给药剂量，移植活性线粒体和灭活线粒体对脓毒症小鼠进行治疗，发现大肠杆菌诱导的小鼠脓毒症模型构建过程中，移植自体或异体来源的活性线粒体能够提高小鼠存活率达30‑50％，具有显著的治疗效果。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN202080002489.XA 2019-10-24 2020-10-23 一种用于预防或治疗脓毒症的药物组合物、试剂盒及其应用和治疗方法 Pending CN114599379A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962925253P 2019-10-24 2019-10-24
US62/925,253 2019-10-24
PCT/CN2020/123169 WO2021078246A1 (zh) 2019-10-24 2020-10-23 一种用于预防或治疗脓毒症的药物组合物、试剂盒及其应用和治疗方法

Publications (1)

Publication Number Publication Date
CN114599379A true CN114599379A (zh) 2022-06-07

Family

ID=75619671

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080002489.XA Pending CN114599379A (zh) 2019-10-24 2020-10-23 一种用于预防或治疗脓毒症的药物组合物、试剂盒及其应用和治疗方法

Country Status (2)

Country Link
CN (1) CN114599379A (zh)
WO (1) WO2021078246A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115005162A (zh) * 2022-07-01 2022-09-06 天津市第一中心医院 贴合临床现状的老年脓毒症血小板减少小鼠模型构建方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090181367A1 (en) * 2002-07-05 2009-07-16 Helene Cote Diagnosis of sepsis using mitochondrial nucleic acid assays
CN104777109A (zh) * 2015-03-16 2015-07-15 首都儿科研究所附属儿童医院 一种脓毒症诊断方法及试剂
WO2017044940A1 (en) * 2015-09-10 2017-03-16 Washington State University Cell membrane-formed nanoscale vesicles and methods of using thereof
CN108796060A (zh) * 2017-07-26 2018-11-13 朱海燕 线粒体mt-co1在筛查脓毒症中的用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090181367A1 (en) * 2002-07-05 2009-07-16 Helene Cote Diagnosis of sepsis using mitochondrial nucleic acid assays
CN104777109A (zh) * 2015-03-16 2015-07-15 首都儿科研究所附属儿童医院 一种脓毒症诊断方法及试剂
WO2017044940A1 (en) * 2015-09-10 2017-03-16 Washington State University Cell membrane-formed nanoscale vesicles and methods of using thereof
CN108796060A (zh) * 2017-07-26 2018-11-13 朱海燕 线粒体mt-co1在筛查脓毒症中的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
QIAN，J.等: "Research progress of transfering mitochondria application in nanotubes in treatment of acute lung injury sepsis" *
肖雅文等: "脓毒症线粒体损伤的研究进展" *

Also Published As

Publication number Publication date
WO2021078246A1 (zh) 2021-04-29

Similar Documents

Publication Publication Date Title
Yasuhara et al. Notch-induced rat and human bone marrow stromal cell grafts reduce ischemic cell loss and ameliorate behavioral deficits in chronic stroke animals
JP2022169781A (ja) 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
US20090053200A1 (en) Method for retarding unhealth manifestations brought by ageing of human beings
CN110724203B (zh) 一种促进tfeb核转位的短肽及基于其的线性短肽和其减轻脑缺血损伤的应用
JP2022095884A (ja) 単離ミトコンドリアを含む関節リウマチの予防または治療のための医薬組成物
AU2004275682B2 (en) Novel use of antisecretory factor
WO2021078246A1 (zh) 一种用于预防或治疗脓毒症的药物组合物、试剂盒及其应用和治疗方法
JPWO2014010206A1 (ja) 免疫寛容誘導剤
US20220211762A1 (en) Pharmaceutical composition for treating sepsis or systemic inflammatory response syndrome, comprising isolated mitochondria as active ingredient
Dodge et al. Effects of donor vitamin A deficiency and pharmacologic modulation of donor T cell retinoic acid pathway on the severity of experimental graft-versus-host disease
RU2508924C1 (ru) Способ профилактики и лечения отторжения почечного трансплантата
US10828338B2 (en) Methods for improving cognition and slowing cognitive impairment using nonviable lyophilized pluripotent stem cells
Tel et al. Effect of surgery on BCNU chemotherapy in a rat brain tumor model
CN115554317A (zh) 一种用于治疗肿瘤的药物组合物、试剂盒及其应用
Chen et al. Alpha-lipoic acid prevents atrial electrical and structural remodeling via inhibition of NADPH oxidase in a rabbit rapid atrial pacing model
US20040076618A1 (en) Placental preparation having antitumor activity
KR102526447B1 (ko) 편도 유래 중간엽 줄기세포의 조정 배지를 포함하는 간질환 예방 또는 치료용 조성물
CN114848836B (zh) 一种偶联物及其在治疗内耳疾病上的应用
JP7348612B2 (ja) 壊死性腸炎治療用組成物
RU2744846C1 (ru) Способ лечения острой печёночной недостаточности
CN114306306B (zh) 2-溴棕榈酸在制备治疗生精功能障碍相关疾病的药物中的应用
KR102242040B1 (ko) 줄기세포의 티오레독신 발현을 증진시키는 방법
US20040161415A1 (en) Antitumor and antiviral medications and method for producing the same
US10925928B2 (en) Method for treating chemotherapy-induced male infertility
RU2362554C2 (ru) Регенерирующее противовоспалительное средство и способы лечения с помощью этого средства

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination